FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International SymposiumBusiness Wire • 07/13/22
FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate UpdatesBusiness Wire • 06/27/22
FSD Pharma submits IND applications to the FDA and Health Canada for Phase 2 clinical trial of FSD-201 to treat an inflammatory disorderProactive Investors • 05/31/22
FSD Pharma Files Investigational New Drug Application (“IND”) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate UpdatesBusiness Wire • 05/31/22
FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research AssociatesBusiness Wire • 05/02/22
FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory BoardBusiness Wire • 04/21/22
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza BokhariBusiness Wire • 04/08/22
FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLCBusiness Wire • 03/15/22
FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000Business Wire • 02/25/22
FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of CanadaBusiness Wire • 01/18/22
FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13thBusiness Wire • 01/04/22
FSD Pharma says board authorizes repurchase by the company of up to 2 million of its subordinate Class B voting sharesProactive Investors • 12/30/21
FSD Pharma says its board has authorized the repurchase by the company of up to 2 million of its subordinate Class B voting shareProactive Investors • 12/30/21
FSD Pharma says it formed new regulatory advisory board, appoints Joga Gobburu and Mary Melnyk as membersProactive Investors • 12/09/21
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D.Business Wire • 12/09/21